On the other hand, no supporting evidence indicates that molecular alterations or mutations in TROP2 may trigger oncogenic transformation, suggesting that TROP2-expressing cancers could belong to the non-oncogene-addicted subtype. Here, TACSTD2 is linked to cancer.